| Filed On | Filing |
|---|---|
| 04 Aug 2026 |
8-K/A: Costs Associated with Exit or Disposal Activities
On June 29, 2026, the Company announced its plan to discontinue the Company’s internal discovery programs and close its Discovery Center of Excellence facility in Birmingham, Alabama (the “Plan”) as part of the Company’s ongoing strategi... |
| 23 Jan 2026 |
8-K/A: Departure/Election of Directors or Officers; Compensation
On January 23, 2026 (the “Closing Date”), BioCryst Pharmaceuticals, Inc., a Delaware corporation (“BioCryst”) completed the transactions contemplated by the Agreement and Plan of Merger, dated as of October 14, 2025 (the “Merger Agreemen... |
| 04 Sep 2018 | 8-K/A: Other Events |
| 04 Aug 2011 | 8-K/A: Results of Operations and Financial Condition; Regulation FD Disclosure |
| 02 May 2006 | 8-K/A: Entry into a Material Definitive Agreement |
| 22 Dec 2005 | 8-K/A: Entry into a Material Definitive Agreement |
| 02 Aug 1996 | 8-K/A: Other Events |
Loading...
